Top

Published in:

Open Access 01-12-2017 | Research

PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia

Authors: Hui Cheng, Chongmei Huang, Xiaoqian Xu, Xiaoxia Hu, Shenglan Gong, Gusheng Tang, Xianmin Song, Weiping Zhang, Jianmin Wang, Li Chen, Jianmin Yang

Published in: Journal of Translational Medicine | Issue 1/2017

Abstract

Background

High expression of proviral integration site for Moloney murine leukemia virus-1 (PIM-1), a serine/threonine kinase, is associated with many cancers. The main purpose of this study were to investigate that the correlation between PIM-1 mRNA levels and clinicopathologic features and its clinical significance in acute myeloid leukemia (AML).

Methods

qRT-PCR was performed for 118 de novo AML and 20 AML complete remission patients and 15 normal individuals. All statistical analysis were performed using Graphpad Prism5 software.

Results

We observed that expression of PIM-1 mRNA was higher in AML patients than in healthy individuals and in complete remission AML patients (P = 0.0177). Further, high PIM-1 mRNA levels were more associated with high-risk FLT3+ AML patients than the FLT3− group (P = 0.0001) and were also associated with clinical factors such as risk stratification (P = 0.0029) and vital status (P = 0.0322). Kaplan–Meier survival analysis indicated that PIM-1 mRNA expression correlated with overall survival (OS), disease free survival (DFS), and relapse rate (RR) in AML patients. Most importantly, the high PIM-1-expressing patients took longer to achieve complete remission than the low expression group (P = 0.001). In addition, the complete remission rate was significantly lower in the high PIM-1 group (P = 0.0277) after induction therapy.

Conclusions

Above results suggest that PIM-1 mRNA levels may be an independent prognostic factor in AML.

Available only for authorised users

Narlik-Grassow M, Blanco-Aparici C, Carnero A. The PIM family of serine/threonine kinases in cancer. Med Res Rev. 2014;34:136–59.CrossRefPubMed

Saris CJ, Domen J, Berns A. The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J. 1991;10:655–64.PubMedPubMedCentral

Magnuson NS, Wang Z, Ding G, Reeves R. Why target PIM-1 for cancer diagnosis and treatment? Future Oncol. 2010;6:1461–78.CrossRefPubMedPubMedCentral

Santio NM, Vahakoski RL, Rainio EM, Sandholm JA, Virtanen SS, Prudhomme M, et al. Pim selective inhibitor DHPCC-9 reveals Pim kinases as potent stimulators of cancer cell migration and invasion. Mol Cancer. 2010;19:279.CrossRef

Santio NM, Eerola SK, Paatero I, Yli-Kauhaluoma J, Anizon F, Moreau P, et al. Pim kinases promote migration and metastatic growth of prostate cancer xenografts. PLoS ONE. 2015;6:e0130340.CrossRef

Zhao Y, Hamza MS, Leong HS, Lim CB, Pan YF, Cheung E, et al. Kruppel-like factor 5 modulates p53 independent apoptosis through Pim-1 survival kinase in cancer cells. Oncogene. 2008;27:1–8.CrossRefPubMed

Santio NM, Salmela M, Arola H, Eerola SK, Heino J, Rainio EM, et al. The PIM-1 kinase promotes prostate cancer cell migration and adhesion via multiple signaling pathways. Exp Cell Res. 2016;342:113–24.CrossRefPubMed

Cen B, Mahajan S, Wang W, Kraft AS. Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. Cancer Res. 2013;73:3402–11.CrossRefPubMedPubMedCentral

Tursynbay Y, Zhang J, Li Z, Tokay T, Zhumadilov Z, Wu D, et al. Pim-1 kinase as cancer drug target: an update. Biomed Rep. 2016;4:140–6.CrossRefPubMed

10.

Warfel NA, Kraft AS. PIM kinase (and Akt) biology and signaling in tumors. Pharmacol Ther. 2015;151:41–9.CrossRefPubMedPubMedCentral

11.

Liu HT, Wang N, Wang X, Li SL. Overexpression of Pim-1 is associated with poor prognosis in patients with esophageal squamous cell carcinoma. J Surg Oncol. 2010;102:683–8.CrossRefPubMed

12.

Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997–2002. Cancer Causes Control. 2008;19:379–90.CrossRefPubMed

13.

Mrózek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman SP, et al. Prognostic significance of the European Leukemia Net standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012;30:4515–23.CrossRefPubMedPubMedCentral

14.

Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079–89.CrossRefPubMedPubMedCentral

15.

Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–74.CrossRef

16.

Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–52.CrossRefPubMed

17.

Medinger M, Lengerke C, Passweg J. Novel prognostic and therapeutic mutations in acute myeloid leukemia. Cancer Genom Proteom. 2016;13:317–29.

18.

Abutalib SA, Tallman MS. Monoclonal antibodies for the treatment of acute myeloid leukemia. Curr Pharm Biotechnol. 2006;7:343–69.CrossRefPubMed

19.

Stein EM. IDH2 inhibition in AML: finally progress? Best Pract Res Clin Haematol. 2015;28:112–5.CrossRefPubMed

20.

Rau RE, Rodriguez BA, Luo M, Jeong M, Rosen A, Rogers JH, et al. DOT1L as a therapeutic target for the treatment of DNMT3A mutant acute myeloid leukemia. Blood. 2016;128:971–81.CrossRefPubMedPubMedCentral

21.

American Cancer Society. Cancer facts and figures 2016. https://old.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf.

22.

Kim KT, Levis M, Small D. Constitutively activated FLT3 phosphorylates BAD partially through pim-1. Br J Haematol. 2006;134:500–9.CrossRefPubMed

23.

Kim KT, Baird K, Ahn JY, Meltzer P, Lilly M, Levis M, et al. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3− mediated cell survival. Blood. 2005;105:1759–67.CrossRefPubMed

24.

Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic clssification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–21.CrossRefPubMedPubMedCentral

25.

Büchner T, Schlenk RF, Schaich M, Döhner K, Krahl R, Krauter J, et al. Acute myeloid leukemia (AML): different treatment strategies versus a common standard arm-combined prospective analysis by the German AML Intergroup. J Clin Oncol. 2012;30:3604–10.CrossRefPubMed

26.

De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6:e441.CrossRefPubMedPubMedCentral

27.

Schetelig J, Schaich M, Schäfer-Eckart K, Hänel M, Aulitzky WE, Einsele H, et al. Study-Alliance-Leukemia: hematopoietic cell transplantation in patients with intermediate and high risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial. Leukemia. 2015;29:1060–8.CrossRefPubMed

28.

Chen J, Kobayashi M, Darmanin S, Qiao Y, Gully C, Zhao R, et al. Hypoxia-mediated up-regulation of Pim-1 contributes to solid tumor formation. Am J Pathol. 2009;175:400–11.CrossRefPubMedPubMedCentral

29.

Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML specific Flt3 mutations. Blood. 2003;101:3164–73.CrossRefPubMed

30.

Fathi AT, Arowojolu O, Swinnen I, Sato T, Rajkhowa T, Small D, et al. A potential therapeutic target for FLT3-ITD AML: PIM-1 kinase. Leuk Res. 2012;36:224–31.CrossRefPubMed

31.

Block KM, Hanke NT, Maine EA, Baker AF. IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell lines. Pancreas. 2012;41:773–81.PubMedPubMedCentral

32.

Li Z, Lin F, Zhuo C, Deng G, Chen Z, Yin S, Gao Z, et al. PIM-1 kinase phosphorylates the human transcri-ption factor FOXP3 at serine 422 to negatively regulate its activity under inflammation. J Biol Chem. 2014;289:26872–81.CrossRefPubMedPubMedCentral

33.

Natarajan K, Bhullar J, Shukla S, Burcu M, Chen ZS, Ambudkar SV, et al. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1 dependent and independent mechanisms. Biochem Pharmacol. 2013;85:514–24.CrossRefPubMed

34.

Goldberg L, Tijssen MR, Birger Y, Hannah RL, Kinston SJ, Schütte J, et al. Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia. Blood. 2013;122:2694–703.CrossRefPubMedPubMedCentral

35.

Bonin S, Larese FF, Trevisan G, Avian A, Rui F, Stanta G, et al. Gene expression changes in peripheral blood mononuclear cells in occupational exposure to nickel. Exp Dermatol. 2011;20:147–8.CrossRefPubMed

36.

Fu L, Fu H, Wu Q, Pang Y, Xu K, Zhou L, et al. High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions. J Transl Med. 2017. doi:10.1186/s12967-017-1260-2.

37.

Wu YB, Lu D, He ZF, Jin CG. PIM-1 polymorphism and PIM-1 expression as predisposing factors of esophageal squamous cell carcinoma in the Asian population. Onco Targets Ther. 2016;17:2919–25.

Title: PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia
Authors: Hui Cheng
Chongmei Huang
Xiaoqian Xu
Xiaoxia Hu
Shenglan Gong
Gusheng Tang
Xianmin Song
Weiping Zhang
Jianmin Wang
Li Chen
Jianmin Yang
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Journal of Translational Medicine / Issue 1/2017
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/s12967-017-1287-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Distinct expression profile of HCMV encoded miRNAs in plasma from oral lichen planus patients

Water T2 as an early, global and practical biomarker for metabolic syndrome: an observational cross-sectional study

Pyruvate kinase M2 and the mitochondrial ATPase Inhibitory Factor 1 provide novel biomarkers of dermatomyositis: a metabolic link to oncogenesis

Porcine model of progressive cardiac hypertrophy and fibrosis with secondary postcapillary pulmonary hypertension

Progress of stem/progenitor cell-based therapy for retinal degeneration

Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page